FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if | no longer subject to |
|-------------------|----------------------|
| Section 16. Form | 4 or Form 5 |
| obligations may c | ontinue. See |
| Instruction 1(b). | |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB Number: | 3235-0287 | | | | | |
|--|-----------|--|--|--|--|--|
| OMB Number: 3235-0 Estimated average burden | | | | | | |
| | 0.5 | | | | | |

| Estimated average burden | |
|--------------------------|-----|
| hours per response: | 0.5 |
| | |

| 1. Name and Address of Reporting Person [*] Clancy Paul J | | | 2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB] | (Check | tionship of Reporting Per all applicable) Director Officer (give title | 10% Owner | |
|---|---------------|----------------|--|------------------------|---|-------------------------------------|--|
| (Last) (First) (Middle) BIOGEN IDEC INC. 225 BINNEY STREET | | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 02/08/2014 | X | below) Executive VP a | Other (specify below) and CFO | |
| (Street) CAMBRIDGE (City) | MA (State) | 02142 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indiv Line) X | idual or Joint/Group Filin Form filed by One Rep Form filed by More tha Person | porting Person | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--|---|------------------------------|---|--------|-----------------------------|---|---|---|-----------|--|
| | | | Code | v | Amount | Int (A) or Price Transactio | | Transaction(s) (Instr. 3 and 4) | | (1150. 4) | |
| Common Stock | 02/08/2014 | | М | | 3,191 | A | \$ <mark>0</mark> | 10,278 | D | | |
| Common Stock | 02/08/2014 | | F | | 1,047 | D | \$315.54 | 9,231 | D | | |
| Common Stock | 02/09/2014 | | М | | 4,691 | A | \$ <mark>0</mark> | 13,922 | D | | |
| Common Stock | 02/09/2014 | | F | | 2,212 | D | \$315.54 | 11,710 | D | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Restricted Stock Unit | \$0 | 02/08/2014 | | М | | | 3,191 | (1) | 02/08/2016 | Common Stock | 3,191 | \$ 0 | 6,385 | D | |
| Restricted Stock Unit | \$0 | 02/09/2014 | | М | | | 4,691 | (1) | 02/09/2015 | Common Stock | 4,691 | \$ <u>0</u> | 4,691 | D | |

Explanation of Responses:

1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

> /s/ Matthew S. Gilman, Attorney in Fact for Paul <u>Clancy</u>

02/11/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

П